467442-12-2

Usage

Uses

Used in Organic Synthesis:
T-butyl 4-formyl-3,5-difluorobenzoate is used as a reagent in organic synthesis for the preparation of various organic compounds. Its unique structural features, including the t-butyl, formyl, and fluorine substituents, make it a valuable intermediate for the synthesis of complex molecules.
Used in Pharmaceutical Production:
T-butyl 4-formyl-3,5-difluorobenzoate is utilized in the production of pharmaceuticals. Its versatile chemical structure allows it to be incorporated into the synthesis of various drug molecules, contributing to the development of new therapeutic agents.
Used in Agrochemical Production:
T-butyl 4-formyl-3,5-difluorobenzoate is also employed in the production of agrochemicals. Its unique properties make it a useful building block for the synthesis of active ingredients in pesticides, herbicides, and other agricultural chemicals, enhancing their efficacy and selectivity.

Upstream product

• 455-40-3 3,5-difluorobenzoic acid 
• 68-12-2 N,N-dimethyl-formamide 

Downstream Products

• 1239956-80-9 2-(4-((5-(2-(3,4-dichlorophenyl)propan-2-yl)-1-(4-fluoro-3-methoxyphenyl)-1H-imidazol-2-ylthio)methyl)-3,5-difluorobenzamido)ethanesulfonic acid 
• 1239963-40-6 methyl 3-(4-((5-(2-(3,4-dichlorophenyl)propan-2-yl)-1-(4-fluoro-3-methoxyphenyl)-1H-imidazol-2-ylthio)methyl)-3,5-difluorobenzamido)propanoate 
• 1239956-79-6 3-(4-((5-(2-(3,4-dichlorophenyl)propan-2-yl)-1-(4-fluoro-3-methoxyphenyl)-1H-imidazol-2-ylthio)methyl)-3,5-difluorobenzamido)propanoic acid 
• 1239956-72-9 tert-butyl 4-((5-(2-(3,4-dichlorophenyl)propan-2-yl)-1-(4-fluoro-3-methoxyphenyl)-1H-imidazol-2-ylthio)methyl)-3,5-difluorobenzoate 
• 1239956-73-0 4-((5-(2-(3,4-dichlorophenyl)propan-2-yl)-1-(4-fluoro-3-methoxyphenyl)-1H-imidazol-2-ylthio)methyl)-3,5-difluorobenzoic acid 
• 1311374-66-9 C₂₆H₂₁Cl₂F₃N₂O₃S₂ 
• 1239956-71-8 4-((5-(2-(4-chloro-3-methoxyphenyl)propan-2-yl)-1-(4-fluorophenyl)-1H-imidazol-2-ylthio)methyl)-3,5-difluorobenzoic acid 
• 1239964-53-4 tert-butyl 4-((5-(2-(4-chloro-3-methoxyphenyl)propan-2-yl)-1-(4-fluorophenyl)-1H-imidazol-2-ylthio)methyl)-3,5-difiuorobenzoate 
• 1239964-18-1 tert-butyl 3,5-difluoro-4-[(methanesulfonyloxy)methyl]benzoate 
• 1239957-04-0 (R)-methyl 2-(4-((5-(2-(4-chloro-3-methoxyphenyl)propan-2-yl)-1-(4-fluorophenyl)-1H-imidazol-2-ylthio)methyl)-3,5-difluorophenylsulfonamido)propanoate 
• 1239957-03-9 4-((5-(2-(4-chloro-3-methoxyphenyl)propan-2-yl)-1-(4-fluorophenyl)-1H-imidazol-2-ylthio)methyl)-3,5-difluorobenzenesulfonic acid 
• 1239963-48-4 4-((5-(2-(4-chloro-3-methoxyphenyl)propan-2-yl)-1-(4-fluorophenyl)-1H-imidazol-2-ylthio)methyl)-3,5-difluorobenzenamine 

Relevant academic research and scientific papers

HETEROCYCLIC COMPOUND INTERMEDIATE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF

Disclosed by the invention is a heterocyclic compound, an intermediate, and a preparation method therefor and an application thereof. Provided by the invention are a heterocyclic compound as shown in formula I, and a stereoisomer, a geometric isomer, a tautomer, a nitrogen oxide, a hydrate, a solvate, a metabolite, an ester, a pharmaceutically acceptable salt or a prodrug thereof. The heterocyclic compound hasa high P2X3 antagonistic activity, and has good selectivity, low toxicity, good metabolic stability and little taste influence.

TETRAHYDRO-BENZOIMIDAZOLYL MODULATORS OF TGR5

The present invention comprises compounds of Formula (I). wherein: R1, R2, R3, R4, R5, R6, R7, R8, X, Z1and Z2 are defined in the specification.

TGR5 AGONISTS

TGR5 agonists of structural formula VIII(Q), wherein X, R1, R2, and R5 are defined in the specification, pharmaceutically acceptable salts thereof, compositions thereof, and use of the compounds and compositions for treating diseases. The invention also comprises use of the compounds in and for the manufacture of medicaments, particularly for treating diseases.

TRIAZOLE AND IMIDAZOLE DERIVATIVES FOR USE AS TGR5 AGONISTS IN THE TREATMENT OF DIABETES AND OBESITY

The present invention comprises TGR5 agonists of structural formula I, wherein X, R1, R2, and R5 are defined herein, as well as N-oxides of them and pharmaceutically acceptable salts thereof. The invention further comprise

SAR and pharmacokinetic studies on phenethylamide inhibitors of the hepatitis C virus NS3/NS4A serine protease

SAR on the phenethylamide 1 (Ki 1.2μM) in the P2- and the P′-position led to potent inhibitors, one of which showed good exposure and low clearance when administered intramuscularly to rat.